The Obama administration may need to make still more changes to protect consumer privacy on the government's health insurance website.» Read More
More than 600,000 people selected insurance plans in the third week on HealthCare.gov, bringing total Obamacare enrollment there above 1 million.
Ex-Health and Human Services Secretary Kathleen Sebelius said the name "Obamacare" is a "very bad brand" that should be scrapped.
Discovering and developing new treatments for diseases is notoriously expensive, but now it could be becoming slightly more financially rewarding.
The health-care sector tends to outperform the overall market during flu season. Who else stands to gain?
Life expectancy is up, smoking is down, and obesity rates are on the rise again according to the new edition of America's Health Rankings.
Jonathan Gruber apologized repeatedly for a series of verbal gaffes about Obamacare, but urged people not to hold it against the law itself.
Two young engineers invented a product that uses LED lights to fight bacteria and decrease risk of infections in hospitals and public spaces.
Valeant Pharmaceuticals is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt and boost its stock price.
The cost of job-based health coverage, including premiums and deductibles, has outpaced wage growth in the past decade, squeezing household budgets.
Most parents say they would consider removing their kids from day care if just 25 percent of the children there lacked up-to-date vaccinations.
Celgene's partnering strategy, which has accelerated in recent years, is starting to bear fruit; many of the most-watched stocks out of ASH fall under its umbrella.
Three small-cap drug firms are consistently the best biotech performers following the start of the American Society of Hematology's annual meeting.
New health insurer Oscar will pay customers up to $20 per month to meet goals offered up by a free wearable fitness device.
Drug giant Merck said it will buy Cubist and its slate of medicines administered in hospitals, many for bacterial infections, for about $9.5 billion.
Doctors who used Genentech's expensive eye drug Lucentis were also among the highest-paid consultants for the company, reports the New York Times.
Drug giant Sanofi is juggling legal and regulatory issues surrounding three cases involving alleged payments or inducements to medical providers.
Large employers could find themselves facing worker lawsuits for violating health-reform laws under the Affordable Care Act.
Much of the influenza virus in the U.S. has mutated and this year's vaccine doesn't provide good protection against it, NBC News reports.
A deadly epidemic that could have global implications is quietly sweeping India, and among its many victims are tens of thousands of newborns dying. The New York Times reports.
A lawsuit accuses drug maker Sanofi and top executives, including its ousted CEO, of a million-dollar kickback scheme to promote diabetes drug sales.
Get the best of CNBC in your inbox